Viz.ai vs Tempus

By valuation, Tempus is the larger company at $8.1B versus $1.2B — a 6.8x difference. Size can also be measured by team: Viz.ai employs 275 people while Tempus has 2500 employees.

Tempus has raised more in total funding at $1.1B, compared to Viz.ai's $289M — a gap of $761M. Combined, the two companies have completed 9 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Viz.ai sits at 66/100. That 18-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Viz.ai was founded by Chris Mansi in 2016. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Viz.ai: Viz.ai is an artificial intelligence healthcare company founded in 2016 that develops clinical decision support software for medical imaging analysis. The company specializes in AI-powered diagnostic tools that assist radiologists and emergency physicians in identifying acute neurological and cardiovascular conditions from medical imaging scans. Viz.ai's core platform uses deep learning algorithms to detect conditions such as stroke, pulmonary embolism, and aortic dissection, prioritizing urgent cases and flagging them for immediate physician review. The company's primary products include stroke detection software and platforms for identifying other time-critical conditions in emergency departments. Viz.ai operates within the broader clinical AI segment, competing with companies developing similar diagnostic imaging solutions. The platform integrates into existing hospital workflows and imaging infrastructure, providing real-time alerts to clinicians. Viz.ai has achieved significant market validation, with its technology adopted across numerous healthcare systems in the United States. The company raised Series D funding at a $1.2 billion valuation, reflecting investor confidence in the clinical AI market. Total funding reached $289 million across multiple rounds. The company's growth trajectory demonstrates expanded adoption among major hospital networks and healthcare providers seeking to improve diagnostic speed and clinical outcomes for emergency conditions. Viz.ai focuses specifically on time-critical emergency conditions where AI-assisted early detection directly impacts patient outcomes and hospital operations. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Tempus got there first, launching in 2015 — that's 1 year of extra runway. Viz.ai didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Viz.ai has about 275 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Viz.ai and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.